Beam's BEAM-302 Shows 84% Mutant Protein Cut, Eyes Accelerated FDA Path
BEAM sits 34% above its 52-week low of $19.355.
Summary
Beam presented updated Phase 1/2 data for BEAM-302 in AATD at ERS 2026. In 29 patients, the 60 mg dose produced sustained AAT levels above the protective 11 µM threshold, cut mutant Z-AAT by 84%, and achieved 93% corrected M-AAT. Safety was acceptable with mostly mild infusion reactions and transient liver enzyme elevations. The company plans an accelerated approval pathway with a 12-month biomarker endpoint and will enroll ~50 more patients. This follows the Q2 update that highlighted BEAM-302 pivotal dosing; today's data adds efficacy detail and a clear regulatory strategy. Premarket shares fell 7.17% to $27.53, likely reflecting profit-taking or safety concerns despite the positive efficacy. Watch for FDA feedback on the accelerated approval plan and enrollment progress in the expansion cohort.
At the time of this announcement, BEAM was trading at $25.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $19.36 to $38.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.